Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.87 |
| ▸ | PGR | P06401 | 3/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | AR | P10275 | 2/20 | 0.87 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | APEX1 | P27695 | 1/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.87 |
| ▸ | IKBKB | O14920 | 1/20 | 0.87 |
| ▸ | CHUK | O15111 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.87 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.87 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL5538540 | 1.00 | HIF1A (0.87) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL120210 | 0.98 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL28873762 | 0.98 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7272 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL4888419 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL124724 | 0.96 | NR3C1 (0.86) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL25306130 | 0.96 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1530977 | 0.96 | HIF1A (0.92) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Betamethasone SCHEMBL27837446 | 0.95 | NR3C1 (0.84) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL3021335 | 0.94 | NR3C1 (0.83) | HIF1ANR3C1CYP3A4HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113820416-A | Method for simultaneously detecting multiple stimulants in animal food | 石家庄海关技术中心 | 2021-12-21 | — | — | CN | claimed |
| US-20240194304-A1 | Prediction Method, Prediction Device, and Prediction Program for New Indication of Desired Known Drug or Equivalent Material Thereof | KARYDO THERAPEUTIX, INC. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-117858663-A | Films with biodegradable polymers | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117849228-A | Biomarker for screening early sexual precocity and application thereof | 裕菁科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-111527407-B | Method for detecting immune related disease index | 株式会社漫丹 | 2023-09-15 | — | — | CN | disclosed |
| CN-116602911-A | Hollow rectal suppository containing medicine | 中国人民解放军军事科学院军事医学研究院 | 2023-08-18 | — | — | CN | disclosed |
| CN-116437928-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with allergic reactions | 日本化学药品株式会社 | 2023-07-14 | — | — | CN | disclosed |
| CN-110339346-B | External skin preparation composition | IGISU株式会社 | 2023-06-27 | — | — | CN | disclosed |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-2489340-A1 | ADHESIVE PATCH | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2489339-A1 | METHOD AND DEVICE FOR PRODUCING ADHESIVE PATCH | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012094618-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | CORCEPT THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| CN-102573722-A | A preparation method of adhesive patch and a device thereof | HISAMITSU PHARMACEUTICAL CO | 2012-07-11 | — | — | CN | disclosed |
| CN-102573723-A | Adhesive patch | HISAMITSU PHARMACEUTICAL INC | 2012-07-11 | — | — | CN | disclosed |
| US-20110130704-A1 | COMBINATION OF A LIGHT RAY AND A LIPASE-BIOCONVERTIBLE COMPOUND FOR IMPROVING SKIN AND/OR HAIR APPEARANCE | L'OREAL (FR) | 2011-06-02 | — | — | US | disclosed |
| EP-2177513-A1 | PHENYLACETIC ACID COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090275668-A1 | Sprayable Gel-Type Skin/Mucosa-Adhesive Preparation and Administration System Using the Preparation | TOKO YAKUHIN KOGYO DABUSHIKI KAISHA (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20030138479-A1 | Plaster | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1293199-A1 | PLASTER | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885HIF1A 4622/4885CYP3A4 1984/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | NR3C1 1/4885HIF1A 4622/4885CYP3A4 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.